Tempus announces collaboration with ifli aimed at supporting development of targeted therapies for follicular lymphoma

Chicago--(business wire)--tempus ai, inc. (nasdaq: tem), a technology company leading the adoption of ai to advance precision medicine and patient care, today announced a new collaboration with the institute for follicular lymphoma innovation (ifli), a global, non-profit, private foundation dedicated to accelerating the development of innovative treatment options for patients with follicular lymphoma (fl). the collaboration aims to develop and make available a real-world multimodal, deidentifie.
TEM Ratings Summary
TEM Quant Ranking